Insight Molecular Diagnostics discussed progress in their blood-based DNA test, GraftAssureDx, initially developed for kidney transplant patients and now seeking FDA approval. The company is preparing to expand this testing to heart transplant rejection, with expert insights from Dr. Max Liebo highlighting its potential to improve heart transplant patient management. This development could simplify monitoring and improve outcomes for transplant recipients.
AMD CEO Lisa Su announced that the company's server revenue is projected to grow by more than 80% in the current half-year period. This growth estimate specifically excludes revenue from AMD's AI accelerator business, highlighting strong demand in ot...
Rosen Law Firm is investigating Suja Life, Inc. for potentially issuing misleading business information after the company lowered its full-year sales outlook, triggering a 46% stock price drop. The firm is preparing a class action lawsuit to recover ...
Early Uber investor Jason Calacanis doubts Bitcoin can reach $250,000 or $1 million, arguing that Michael Saylor's aggressive accumulation and complex financial strategies have disrupted the Bitcoin market. Calacanis criticizes MicroStrategy's approa...
Rosen Law Firm is investigating claims that America's Car-Mart misled investors with business information, leading to a significant stock drop after a poor Q1 earnings report. The stock fell 18.2% following news of a larger-than-expected loss per sha...
Bitcoin surged past $65,000, its highest since mid-August, driven by a rebound in US equities and easing geopolitical tensions. Spot Bitcoin ETFs in the US saw nearly $300 million in net inflows, signaling renewed institutional interest. Technical an...
